Literature DB >> 22976939

A family with discordance between malignant hyperthermia susceptibility and rippling muscle disease.

Jimmy Sundblom1, Atle Melberg, Franz Rücker, Anja Smits, Gunilla Islander.   

Abstract

Rippling muscle disease (RMD) is a disorder that affects striated muscle and involves disturbances in calcium homeostasis. Malignant hyperthermia susceptibility (MHS) is a potentially lethal disorder, characterized by extreme hypermetabolism and muscle rigidity/rhabdomyolysis during anesthesia with potent inhalational agents, in otherwise healthy individuals. The aim of this report was to search for a correlation between RMD and MHS in members of a family in which both disorders were present. Ten members of a large Swedish family segregating RMD were tested for MHS prior to establishing an RMD diagnosis. Results from diagnostic RMD investigations and anesthesia outcomes were collected and cross-referenced to evaluate whether phenotype variations could be predicted by in vitro contracture test (IVCT) results suggestive of MHS. No correlation was found between individual RMD phenotypes and the IVCT results. There were no recorded adverse reactions to anesthesia, and RMD and MHS did not co-segregate. We conclude that RMD patients should not, on the basis of our present knowledge, be classified as having MHS; however, an increased surveillance for MH reactions is recommended in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22976939     DOI: 10.1007/s00540-012-1482-7

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  24 in total

1.  A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita thomsen.

Authors:  T Torbergsen
Journal:  Acta Neurol Scand       Date:  1975-03       Impact factor: 3.209

2.  The association of malignant hyperthermia and unusual disease: when you're hot you're hot or maybe not.

Authors:  Peter J Davis; Barbara W Brandom
Journal:  Anesth Analg       Date:  2009-10       Impact factor: 5.108

3.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Caveolinopathy--new mutations and additional symptoms.

Authors:  Ahmed Aboumousa; Jessica Hoogendijk; Richard Charlton; Rita Barresi; Ralf Herrmann; Thomas Voit; Judith Hudson; Mark Roberts; David Hilton-Jones; Michelle Eagle; Kate Bushby; Volker Straub
Journal:  Neuromuscul Disord       Date:  2008-06-25       Impact factor: 4.296

Review 5.  Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options.

Authors:  Joan Benca; Kirk Hogan
Journal:  Anesth Analg       Date:  2009-10       Impact factor: 5.108

6.  Expression of the muscular dystrophy-associated caveolin-3(P104L) mutant in adult mouse skeletal muscle specifically alters the Ca(2+) channel function of the dihydropyridine receptor.

Authors:  Norbert Weiss; Harold Couchoux; Claude Legrand; Christine Berthier; Bruno Allard; Vincent Jacquemond
Journal:  Pflugers Arch       Date:  2008-05-29       Impact factor: 3.657

7.  The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry.

Authors:  Roger A Bannister; Isaac N Pessah; Kurt G Beam
Journal:  J Gen Physiol       Date:  2009-01       Impact factor: 4.086

Review 8.  Dantrolene--a review of its pharmacology, therapeutic use and new developments.

Authors:  T Krause; M U Gerbershagen; M Fiege; R Weisshorn; F Wappler
Journal:  Anaesthesia       Date:  2004-04       Impact factor: 6.955

9.  Alterations of excitation-contraction coupling and excitation coupled Ca(2+) entry in human myotubes carrying CAV3 mutations linked to rippling muscle.

Authors:  Nina D Ullrich; Dirk Fischer; Cornelia Kornblum; Maggie C Walter; Ernst Niggli; Francesco Zorzato; Susan Treves
Journal:  Hum Mutat       Date:  2011-02-03       Impact factor: 4.878

Review 10.  Malignant hyperthermia.

Authors:  Henry Rosenberg; Mark Davis; Danielle James; Neil Pollock; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2007-04-24       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.